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Abstract: The myelodysplastic syndromes (MDS) are clonal stem cell disorders, characterized by ineffective and dysplastic 
hematopoiesis. The genetic and epigenetic pathways that determine disease stage and progression are largely unknown. In 
the current study we used gene expression microarray methodology to examine the gene expression differences between 
normal hematopoietic cells and hematopoietic cells from patients with MDS at different disease stages, using both unselected 
and CD34+ selected cells. Signiﬁ  cant differences between normal and MDS hematopoietic cells were observed for several 
genes and pathways. Several genes promoting or opposing apoptosis were dysregulated in MDS cases, most notably MCL1 
and EPOR. Progression from RA to RAEB(T) was associated with increased expression of several histone genes. In addi-
tion, the RAR-RXR pathway, critical for maintaining a balance between self-renewal and differentiation of hematopoietic 
stem cells, was found to be deregulated in hematopoietic cells from patients with advanced MDS compared to patients with 
refractory anemia. These ﬁ  ndings provide new insights into the understanding of the pathophysiology and progression of 
MDS, and may guide to new targets for therapy. Taken together with previous published data, the present results also 
underscore the considerable complexity of the regulation of gene expression in MDS.
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Introduction
The myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of the hemato-
poietic stem cells [1, 2]. The natural history of MDS is that of progressive cytopenia with increasing 
transfusion needs, infectious and bleeding complications or alternatively, evolution to secondary AML 
[1, 2]. While relatively simple clinical and pathologic scoring systems with prognostic relevance have 
been developed, the molecular mechanisms involved in evolution of the disease are largely unknown 
[3, 4]. Identifying molecular markers of MDS may allow for a more accurate assessment of the prognosis 
and potentially identify new targets for therapy.
The genetic lesions so far identiﬁ  ed in MDS incompletely describe the biology and heterogeneity 
of the disease. Clonal karyotypic abnormalities are observed in approximately 40–50% of patients with 
primary MDS, and 90% of therapy-related MDS [2, 5]. Mutations important in denovo AML, for 
example mutations in RAS proto-oncogenes and FLT3 internal tandem duplications (ITD), have been 
described in 5%–20% of MDS patients and are variably associated with disease progression [3, 6–9]. 
Beside overt genetic lesions, epigenetic lesions may also play a roll in the development of MDS. Hyper-
methylation has been described in many malignancies including MDS and may be associated with 
disease development, progression and prognosis [10–14]. For example, p15 promoter hypermethylation 
has been shown to be associated with MDS progression to AML in some studies [3, 15]. However, none 
of these alterations are speciﬁ  c for MDS and the underlying molecular causes of MDS have remained 
poorly understood.
The vast number of genetic and epigenetic disturbances in MDS makes investigations to identify 
potential common pathways that may involved in disease development and progression challenging. 
Oligonucleotide microarrays have been found to be an excellent tool to study biology and identify 
potential prognostic factors in many forms of malignancies, including MDS. This platform allows 138
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examination of thousands of genes using a single 
sample. In the current study we used oligonucle-
otide microarrays to determine how the genetic 
expression proﬁ  le differs between healthy hema-
topoietic cells and hematopoietic cells from 
patients with MDS, and to identify genes and 
pathways that might be relevant for MDS evolution 
and progression.
Materials and Methods
Patients
Mononuclear cells (N = 35) or puriﬁ  ed CD34+ 
cells (N = 8) from the marrow of 43 MDS patients 
were studied. Patients were sub-grouped according 
to the French-American-British (FAB) classiﬁ  ca-
tion [16] into refractory anemia (RA, N = 18), 
refractory anemia with ringed sideroblasts (RARS, 
N = 11), refractory anemia with excess blasts 
(RAEB, N = 8), and refractory anemia with excess 
blasts in transformation (RAEB-t, N = 1). In addi-
tion, we included one patient with unclassiﬁ  ed 
MDS, one patient with a mixed MDS/myelopro-
liferative picture, and three patients with AML that 
had evolved from MDS. Three patients had 5q 
deletion, however not as an isolated lesion, but as 
part of complex cytogenetic abnormalities. Mono-
nuclear (N = 10) or puriﬁ  ed CD34+ bone marrow 
cells (N = 14) from 24 healthy subjects were used 
as controls. Samples from ﬁ  ve normal bone mar-
rows, four patients with low grade MDS (RARS 
or RA), and seven patents with high grade MDS 
(RAEB-1 or RAEB-2) not used in the microarray 
studies were used for PCR validation studies of 
MCL1 expression. Some of the patients had 
received treatment in the past, including chemo-
therapy, erythropoietin or thalidomide, but no 
treatment was given within 4 weeks of sample 
acquisition. All patients and healthy donors had 
given informed consent according to the require-
ments of the Institutional Review Board.
Sample preparation
Heparinized bone marrow samples were obtained 
by aspiration from the posterior iliac crest. Mono-
nuclear cells were separated by density gradient 
centrifugation through Ficoll-Hypaque. CD34+ 
cells were puriﬁ  ed by two rounds of high-gradient 
magnetic cell separation using autoMACS (Milt-
enyi Biotec Inc, Auburn, CA) with superparamagnetic 
microbead labeling of CD34+ cells. Total RNA 
was extracted using TRIzol (Invitrogen, Carlsbad, 
CA.) according to the manufacturer’s protocol. All 
RNA samples were analyzed on an HP 2100 bio-
analizer (Aglient Technologyies, Palo Alto, CA 
USA) to ensure the integrity of total RNA prior to 
use in microarray assays [17].
Oligonucleotide microarray gene 
expression
RNA obtained from mononuclear cells was pre-
pared according to the standard Affymetrix proto-
col (GeneChip Expression Analyses Technical 
Manual (http; //www.affymetrix.com/support/tech-
nical/manual/expression_manual.affx). For CD34+ 
cells, RNA was prepared using a single stranded 
linear ampliﬁ  cation protocol (SLAP) prior to RNA 
labeling and hybridization [17]. Fragmented, bio-
tinylated cDNA was hybridized to an Affymetrix 
HG-U133 microarray according to the manufac-
turer’s protocol.
Data analysis
DAT ﬁ  les for individual samples were generated 
using Affymetrix MAS 5.0 software. Target signals 
for probe sets were scaled to 500 for analyses. The 
detection algorithm was based upon default set-
tings per Affymetrix recommendations (https://
www.affymetrix.com/support/downloads/manu-
als/data_analysis_fundamentals_manual.pdf).
Signals were transformed into log2 intensity. 
Normalization was performed using the R 2.2.1 
software [18]. The expression data was then ana-
lyzed using SAM 2.2.1 (Signiﬁ  cance Analysis of 
Microarrays (SAM), Stanford, CA)[19] or Gene-
Plus 1.2 (http://www.enodar.com/technology6.
htm) for speciﬁ  c gene expression analysis and 
Gene Set Enrichment Analysis software (GSEA 
v1.0, Broad Institute, MIT, Cambridge, MA) for 
pathway analysis [20]. We selected a false discov-
ery rate (FDR) of 5% to determine statistically 
signiﬁ  cant up or down regulated genes in SAM 
[21]. Hierarchical clustering was performed using 
the dChip software available at http://biosun1.
harvard.edu/complab/dchip/.
For the analysis of MCL1 levels and transcript 
ratio in different MDS disease stages, a global 
p-value was derived using linear regression and 
tested in the null hypothesis that the mean tran-
script ratios were the same across normal, RA, and 139
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advanced phase MDS. The signiﬁ  cant test for trend 
used linear regression of the mean of the transcript 
across each group, where each group was assigned 
values 1, 2, and 3 for normal, low, and advanced 
MDS, respectively.
PCR validation of MCL1
To validate the gene expression of MCL1 in normal 
and MDS hematopoesis, we developed quantitative 
RT-PCR assays. Samples from ﬁ  ve normal bone 
marrows, four patients with low grade MDS 
(RARS or RA), and seven patents with high grade 
MDS (RAEB-1 or RAEB-2) not used in the micro-
array studies were analyzed. For MCL1, the two 
alternative splice variants were ampliﬁ  ed sepa-
rately, producing a full-length transcript (T×1) 
associated with anti-apoptosis, and the alterna-
tively spliced, smaller transcript (T×2) that is pro-
apoptotic. Quantitative PCR validation for MCL1 
splice variants was performed on an ABI 7900 HT 
Fast Real-Time PCR System. Thermocycler condi-
tions were set at: 50 °C for 2 min, 95 °C for 
10 min, and 40 cycles at 95 °C for 15 sec and 
60 °C for 1 min. A common primer sequence was 
used for the forward MCL1 primer (E×1): 
5’-GAAGGCGCTGGAGACCTTAC-3’). 
MCL1-T×1 (MCL1-T×1R) and MCL1-T×2 
(MCL1-T×1R) reverse primer sequences were 
5’-TTTCCGAAGCATGCCTTGG-3’ and 
5’-ACTCCACAAACCCATCCTTGG-3’, respec-
tively. All probes were FAM-TAMRA; the MCL-1 
probe sequence was 5’-ATGGCGTGCAGCG-
CAACCAC-3’. Controls genes were obtained from 
cloned 2.1 TOPO vector plasmids. The size of the 
MCL1-T×1 and MCL1-T×2 inserts was 517 bp, 
and 269 bp respectively.
Results
To explore the changes in gene expression that 
occur with the evolution of MDS from normal 
hematopoietic progenitor cells and during disease 
progression from RA to RAEB and transformation 
into secondary AML, we used two general strate-
gies. First, we identiﬁ  ed expression changes com-
mon to all MDS cases compared to normal bone 
marrow, and secondly, we examined gene expres-
sion in MDS cases that correlated with disease 
subtypes. Since it is not clear to what extent the 
biology of MDS is determined only by the malig-
nant “stem cell” and what the entire cellular envi-
ronment contributes, separate analyses were 
performed in unselected and CD34+ selected 
populations of both MDS and normal hematopoi-
etic cells.
Gene expression in MDS compared 
to normal bone marrow
We ﬁ  rst compared unselected marrow mononuclear 
cells from 35 patients with MDS and 10 healthy 
donors. Unsupervised hierarchical clustering 
showed complete segregation between normal 
bone marrow and MDS marrow (Fig. 1A). How-
ever, there was no segregation between the differ-
ent morphologic subtypes of MDS (Fig. 1A), 
underscoring the difﬁ  culty of describing MDS 
biology by morphology alone.
In comparing all MDS cases to normal bone 
marrow, 516 genes were up-regulated and 2107 
were down-regulated in the MDS samples (Supple-
mentary Table 1). The top up-regulated genes in 
MDS included: the HSPA1A (heat shock 70 kDa 
protein), CEACAM6 (carcinoembryonic antigen-
related cell adhesion), DEFA1/4 (defensin alpha 1 
and 4), GFI1 (growth factor independent 1) and 
TCN1 (transcobalamin 1). Among the top down-
regulated genes were CREM (a cAMP responsive 
element modulator), SC5D (sterol-C5-desaturase 
(ERG3 delta-5-desaturase homolog, fungal)-like), 
PIK3R1 (phosphoinositide-3-kinase, regulatory 
subunit 1 (p85 alpha) and IRF4 (interferon regula-
tory factor 4). GSEA analysis was then used to 
discover annotated biological pathways over-
represented by genes that were up or down-
regulated in MDS compared to normal bone 
marrow. The pathways most signiﬁ  cantly enriched 
in abnormally regulated genes in MDS were ves-
icle transport, glycogen metabolism, chaperone 
modulated interferon signaling, and the pentose 
phosphate pathway.
We next compared gene expression in CD34+ 
selected cells from MDS and normal bone marrow 
to examine potential changes occurring primarily 
in the putative MDS “stem cell”. We identiﬁ  ed 704 
genes that were up-regulated and 826 genes that 
were down-regulated in the CD34+ cells from 
MDS patients compared to CD34+ cells from 
healthy donors (Supplementary Table 2). In com-
paring the genes that differed signiﬁ  cantly between 
unsorted samples and puriﬁ  ed CD34+ cells, we 
observed an overlap of 12 genes that were consis-
tently up-regulated in both the unselected and 
CD34+ selected cells, and 95 genes that were 140
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consistently down-regulated in both the unselected 
and CD34+ selected cells (Table 1, full list in 
Supplementary Table 3). These genes are likely to 
be highly relevant as markers of biological activity, 
as well as targets for diagnostic and therapeutic 
tools. The top overlap genes and their expression 
in all samples are shown in Figure 1B, 1C and 
Figure 2. The overlap genes fall into several rel-
evant biological categories. Interestingly, many 
genes were deregulated in favor of increased apop-
tosis: decreased expression in the anti-apoptotic 
regulator MCL1, the erythropoetin receptor EPOR, 
and TNF anti-apoptotic modulator TNFAIP3, and 
an increased expression in Ca+2 activated nucleo-
tidase CANT1, and the inhibitory receptor LAIR1. 
There was no association of EPOR level and past 
use of erythropoetin. Dysregulated immune func-
tion and cytokine expression have been implicated 
in MDS, and in this analysis are highlighted by the 
increased expression of the CD4/CD8 cytokine 
CCL18, the decreased expression of the “master” 
control gene for class II MHC expression CIITA, 
and the decreased expression of CXCR4, the recep-
tor for stroma derived factor 1.
Gene expression in RA compared 
to advanced MDS
The signals that lead to progression from RA to 
more advanced disease are poorly understood. We 
compared unselected mononuclear cells from 16 
patients with RA to unselected mononuclear cells 
from 11 patients with advanced MDS, again using 
normal bone marrow as reference. Several genes 
were expressed differently in normal bone marrow, 
RA and advanced disease (Table 2, Supplementary 
N
B
M
 
1
N
B
M
 
3
N
B
M
 
7
N
B
M
 
4
N
B
M
 
9
N
B
M
 
2
N
B
M
 
5
N
B
M
 
6
N
B
M
 
8
N
B
M
 
1
0
R
A
E
B
 
2
R
A
 
7
R
A
 
1
1
R
A
 
3
R
A
 
4
R
A
E
B
 
6
R
A
E
B
 
7
R
A
E
B
 
1
R
A
E
B
T
R
A
 
2
A
M
L
 
2
R
A
 
1
2
R
A
 
1
0
R
A
R
S
 
3
R
A
R
S
 
4
R
A
E
B
 
5
M
D
S
u
n
c
l
a
s
s
i
f
i
e
d
R
A
 
1
5
R
A
 
1
R
A
 
8
R
A
 
5
A
M
L
 
3
R
A
 
1
4
R
A
R
S
 
5
R
A
 
1
3
R
A
E
B
 
4
R
A
R
S
 
2
R
A
R
S
 
6
R
A
 
1
6
R
A
R
S
 
7
R
A
 
6
R
A
 
9
R
A
E
B
 
3
R
A
R
S
 
1
A
M
L
 
1
NBM MDS
dG e n e s
e a b c d fG e n e s g ab c e d Genes
A
C B
Figure 1. A. Hierarchical clustering of 1,000 differentially expressed genes in normal marrow and marrow from MDS patients. Each 
row represents a single probe set and each column a separated normal or MDS marrow sample. Blue coloring represents down-regulated 
genes in MDS compared to normal, while red represents up-regulated genes in MDS. Unsupervised hierarchical clustering showed complete 
segregation between normal bone marrow (n = 10) and MDS (n = 35), but no segregation between the different stages of MDS.
B, C. Heat map of up- and down-regulated genes in unselected mononuclear and CD34+ selected cells from MDS marrow and 
normal marrow samples. B) Comparison of gene expression in unselected mononuclear cells in MDS and normal bone marrow: “a”—nor-
mal bone marrow samples; “b”—RA samples; “c”—RARS; “d”—RAEB; “e”—RAEB-t; “f”—unclassiﬁ  ed MDS; and “g”—AML cases arising 
from antecedent MDS. C) Comparison of gene expression in CD34+ selected cells: “a”—normal marrow; “b”—RA; “c”—RARS; “d”—RAEB; 
and “e”—a case of MDS/MPS (a mixed MDS/myeloproliferative picture).142
Bar et al
Translational Oncogenomics 2008:3 
Table 4). Among these genes are MAX (MYC 
associated factor X), HIST2H2BE (histone 2, 
H2be), HIST2H2AA (histone 2, H2aa), 
HIST1H2BG (histone 1, H2bg) and TNFRSF1A 
(tumor necrosis factor receptor superfamily, mem-
ber 1A) which were increasingly expressed with 
the evolution of RA from normal bone marrow and 
with progression from RA to more advanced stages 
of MDS (Fig. 3). ASGR2 (asialoglycoprotein 
receptor 2), TGFB1 (transforming growth factor, 
beta 1) IDH3B (isocitrate dehydrogenase 3 NAD+ 
beta) and EPB41L3 (erythrocyte membrane pro-
tein band 4.1-like 3) were down regulated in RA 
compared to normal bone marrow, and were further 
down-regulated in advanced MDS (Fig. 3). We next 
searched for changes in biological pathways asso-
ciated with MDS disease progression. Using the 
GSEA software we identiﬁ  ed statistically signiﬁ  -
cant enrichment in genes involved in the Rac 1 cell 
motility signaling pathway and the RAR-RXR 
pathway with advanced disease.
Validation studies of MCL1
In validation studies (Fig. 4), the expression of both 
the longer anti-apoptotic transcript (T×1) and the 
shorter pro-apoptotic transcript (T×2) variants of 
MCL1 decreased signiﬁ  cantly from normal bone 
marrow to low grade, and high grade MDS (global 
signiﬁ  cance levels of T×1 and T×2 when compar-
ing normal, low, and high grade MDS were 
p = 0.03 and p = 0.007, respectively). Moreover, 
there was a shift of the ratio of the anti-apoptotic/
pro-apoptotic mRNA level in these three states, 
with a T×1/T×2 of 8.4 for normal bone marrow, 
4.8 for low grade MDS, and 2.6 for high grade 
MDS (global signiﬁ  cance p = 0.0008, test of trend 
p = 0.0001). Thus, MDS and progression of MDS 
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were associated with not only a global decline in 
MCL1 level, but a shift in transcript towards a 
pro-apoptotic bias.
Discussion
MDS comprises a heterogeneous group of clonal 
disorders that are characterized by aberrant dif-
ferentiation in multiple hematopoietic cell lineages 
and are thought to involve hematopoietic stem cells 
[1, 2]. However, there is mounting evidence that 
the disease process is not entirely stem cell-
autonomous and that signals derived from more 
differentiated cells, in particular monocytes and T 
lymphocytes, and from the marrow stroma affect 
the disease process [22–30]. We, therefore, per-
formed an analysis of gene expression in both 
unselected mononuclear cells and in selected 
CD34+ cells from MDS marrow in comparison to 
the analogous cell populations from normal mar-
row. Our results identiﬁ  ed 2623 genes with expres-
sion differences between unselected marrow 
mononuclear cells from healthy donors and MDS 
patients and 1530 genes with expression differences 
Table 2. Top genes differentially expressed in Advanced Disease (RAEB and RAEBT) compared to RA compared 
to normal bone marrow.
Gene symbole Gene description Linear
slope
1
P (linear
slope)
Up regulated genes:
HIST2H2BE histone 2, H2be 1.16 0.00
MAX MAX protein 0.47 0.00
HIST2H2AA histone 2, H2aa 1.52 0.00
TNFRSF1A tumor necrosis factor receptor superfamily, 
member 1A
0.83 0.00
HIST1H2BG histone 1, H2bg 1.08 0.00
ARHGEF2 rho/rac guanine nucleotide exchange factor 
(GEF) 2
0.37 0.00
SNX19 sorting nexin 19 0.29 0.00
C1RL complement component 1, 
r subcomponent-like
0.87 0.00
H2BFS H2B histone family, member S 1.37 0.01
HIST1H2BF histone 1, H2bf 0.97 0.01
Down regulated genes:
ASGR2 asialoglycoprotein receptor 2 −1.75 0.00
RNASE4 ribonuclease, RNase A family, 4 −1.11 0.00
IDH3B isocitrate dehydrogenase 3 (NAD+) beta −0.36 0.00
EPB41L3 erythrocyte membrane protein band 
4.1-like 3
−1.70 0.00
TGFBI transforming growth factor, beta-induced, 
68 kDa
−1.80 0.00
CSPG2 Chondroitin sulfate proteoglycan 2 
(versican)
−1.39 0.00
KIAA0399 (ZZEF1) zinc ﬁ  nger, ZZ-type with EF-hand domain 1 −1.17 0.00
FLJ22222 hypothetical protein FLJ22222 −0.98 0.00
IL15 interleukin 15 −0.67 0.01
CLIC3 chloride intracellular channel 3 −1.86 0.01
1Linear Slope—Change of value in the dependent variable (gene expression change) per unit of independent variable (disease stage);
The changes in gene expression in the different stages of MDS.144
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between CD34+ cells from healthy donors and 
MDS patients. Compared to normal marrow, MDS 
was associated with an aberrant expression of 
genes involved in apoptosis, including a decreased 
expression of MCL1 and EPOR1, and these 
changes were present both in non-selected and 
CD34+ selected cell populations. Moreover, the 
PML gene and genes of the RAR-RXR pathway 
were found to be associated with the diagnosis of 
MDS and with advanced disease, respectively, 
suggesting disruptions of the normal differentiation 
pathway.
Several genes associated with the promotion of 
a pro-apoptotic state were identiﬁ  ed, including 
anti-apoptotic regulator MCL1, the erythropoetin 
receptor EPOR, and TNF anti-apoptotic modulator 
TNFAIP3. Down regulation of MCL1 is consistent 
with the increased rate of apoptosis observed in 
MDS [26, 31–35]. The protein encoded by the 
MCL1 gene belongs to the Bcl-2 family, known to 
be regulator of programmed cell death. MCL1 has 
been shown to be essential in the survival of 
hematopoetic stem cells, as inducible deletions of 
MCL1 in murine models results in a profound loss 
of bone marrow function, including a loss of hema-
topoietic stem cells [36]. MCL1 activity appears 
to be required for neutrophil, but not for macro-
phage survival, [37] suggesting the possibility of 
lineage specific or differentiation dependent 
activity. Alternative splicing of the MCL1 gene 
results in two transcript variants encoding distinct 
isoforms. The longer gene product (isoform 1; T×1) 
enhances cell survival by inhibiting apoptosis, 
while the alternatively spliced shorter gene product 
(isoform 2; T×2) promotes apoptosis and is death-
inducing [38]. These ﬁ  ndings are reminiscent of 
those described for the long and short splice vari-
ants of the death signal inhibitory protein FLIP in 
MDS, [39] suggesting that regulation of splice 
variants at the transcriptional level is involved in 
the determination of cell death in MDS. Our data 
show that not only was MCL1 expression decreased 
in MDS compared to normal hematopoetic cells, 
but ratio of long/short transcripts shifted in favor 
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of a more pro-apoptotic state. Would such a pattern 
be compatible with the general observation that 
apoptosis in marrow cells overall tends to decrease 
as MDS progressed to more advanced stages? [40] 
The results appear counterintuitive. However, we 
have previously shown that the rate of apoptosis 
differs between clonal and non-clonal hematopoi-
etic cells, and the relative proportions of those cell 
populations change with progression of MDS [41]. 
Further we observed that expression of the short 
splice variant of FLIP, characterized anti-apoptotic 
protein, showed a positive correlation with the 
extent of apoptosis [39]. Taken together with the 
lineage specificity of MCL1 as described by 
Dzhagalove et al. [37] it is conceivable that a pro-
apoptotic effect of MCL1 in advanced MDS is 
expressed only in subset of cells, but does not 
interfere with increasing proliferation of the mali-
gnant clone. Such a model would also be consistent 
with the observed overall decline in expression of 
this gene as MDS progresses (see results).
The erythropoietin receptor (EPOR) is a 
member of the cytokine receptor family. Upon 
erythropoietin binding, the erythropoietin receptor 
activates the Jak2 tyrosine kinase, which in turn 
activates various intracellular signaling pathways, 
including, Ras/MAP kinase, phosphatidylinositol 
3-kinase and STAT transcription factors [42]. 
EPOR has an anti-apoptotic function via the Akt-
pathway, and signaling via the erythropoietin 
receptor promotes erythroid cell survival, particu-
larly in patients with MDS [43–45]. Thus, the 
down-regulation of both MCL1 and EPOR may 
play a role in the dysregulation of apoptosis in 
hematopoetic cells leading to ineffective hemato-
poiesis in MDS. It is clear, however, that the pattern 
of expression of MCL1 and EPOR by themselves 
can not explain satisfactorily the extent of apopto-
sis and proliferation dysregulations at different 
stages of MDS. Other factors are involved, and 
studies of puriﬁ  ed cell populations, simultaneously 
analyzing the impact of various signals will be 
necessary [46].
Of special biological interest are the MAX 
(MYC associated factor X) and PML (promyelo-
cytic leukemia) genes, which were found to be 
up-regulated in both unselected mononuclear cells 
and CD34+ selected cells in MDS compared to 
normal bone marrow and which showed a correla-
tion with progression to advanced disease. The 
protein encoded by the MAX gene is a transcription 
factor that interacts with the MYC oncoprotein to 
form homodimers and heterodimers. Rearrange-
ment among these dimer forms provides a complex 
system of transcriptional regulation [47]. There-
fore, alteration in transcription regulation resulted 
by up regulation of the MAX gene might play a 
role in the pathophysiology of MDS. In addition, 
the correlation with progression to advanced dis-
ease and the fact that the MAX gene was found to 
be up regulated in both CD34+ selected cells and 
unselected marrow cells make this gene a candidate 
marker for disease progression. The protein 
encoded by the PML gene is a member of the tri-
partite motif (TRIM) family. This phosphoprotein 
localizes to nuclear bodies where it functions not 
only as a transcription factor but also as a tumor 
suppressor. Its expression is cell-cycle related and 
regulates the p53 response to oncogenic signals 
[48]. The gene is also involved in the translocation 
of the retinoic acid receptor alpha gene associated 
with acute promyelocytic leukemia (APL) [49]. A 
Further suggestion of the importance of PML and 
the RARA pathway in MDS disease progression 
is the deregulation of the RAR-RXR pathway in 
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Figure 4. Quantitative RT-PCR assay of MCL1.
A. Expression of MCL1 anti-apoptotic transcript (t×1) and pro-
apoptotic transcript (t×2). Values on the y axis represent MCL1 
expression relative to endogenous control (beta-2-microglobulin) in 
normal bone marrow (n = 5), RA patients (n = 4) and MDS patients with 
advanced disease (n = 7). Both normal and MDS marrows were obtained 
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B. Relative expression of MCL1 anti-apoptotic transcript (t×1) 
versus pro-apoptotic transcript (t×2). Values on the y axis repre-
sent the relative expression of MCL1 t×1 versus t×2 for each of the 
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the advanced MDS noted in our analysis. RXR and 
RAR are nuclear receptors that bind either all-trans 
retinoic, 9-cis retinoic acid, or other retinoid 
ligands [50]. Ligand binding induces a conforma-
tional change in the receptors which results in 
dissociation of the co-repressors and binding of 
co-activators with histone acetylase activity [50]. 
The retinoic acid pathway is critical for maintain-
ing a balance between self-renewal and differen-
tiation of hematopoetic stem cells, [51, 52] and 
deregulation of the RAR-RXR pathway, as was 
shown in our study, may affect differentiation and 
self-renewal, and thereby allow RA to progress to 
acute leukemia.
Three histone genes (HIST2H2BE, HIST-
2H2AA, HIST1H2BG) were found to be up-
regulated in MDS compared to normal bone 
marrow, and moreover found to be correlated with 
advanced disease. The expression of speciﬁ  c his-
tone classes dictate changes in chromatin structure 
and gene expression, and inﬂ  uences various path-
ways, including cell cycle progression [53–55]. In 
addition, there is considerable evidence that histone 
H1 also functions as a non-speciﬁ  c repressor of 
transcription [56]. Moreover, post-translational 
modiﬁ  cations of histones by histone acetylation 
and deacetylation play a role in tumorgenesis. 
Histone deacetylases are promising targets in drug 
development for cancer therapy [57]. Given that 
our data suggest that aberrations in histone biology 
are involved in MDS progression, their may be a 
rationale for using these agents to stem progression 
of early MDS, especially in combination with 
agents that block apoptosis, as discussed above.
Several studies have examined gene expression 
in MDS, using either puriﬁ  ed CD34+ or unselected 
mononuclear cells [58–62]. There is little overlap 
between the genes identiﬁ  ed across those studies 
or our current results. Such discrepancies are not 
uncommon in gene expression studies, and likely 
result from differences in cell types studied 
(CD34+ versus mononuclear cells), analytic tech-
niques to deﬁ  ne signiﬁ  cant genes, and composi-
tion of the cohorts of patients studied. For 
example, the study by Pellagatti et al. [60] exam-
ined CD34+ cells from 55 MDS patients obtained 
from multiple centers, and showed that MDS cells 
had gene signatures enriched in interferon 
response genes. Of the 55 patents, 20 had the 5q- 
chromosomal aberration. Patients with 5q- MDS 
are unusually sensitive to the drug lenalidomide, 
and have recently been shown to have a unique 
gene expression signature using unselected 
mononuclear cells [63].
Since it is unknown which cell population, 
CD34+ selected or unselected mononuclear cells, 
best describes the pathology of MDS, and given 
that various studies have used both types of sam-
ples, we performed both types of arrays, and 
focused on genes found to be dysregulated in both 
cell populations. Thus, we consider our gene selec-
tion to be fairly robust. We are comforted by the 
fact that the most relevant genes identiﬁ  ed in the 
present analysis seem biologically relevant: alter-
ations of differentiation and proliferation pathways 
(PML, RAR-RXR, MAX), involvement in apop-
tosis (MCL1, EPOR) and regulation of hemato-
poiesis (TNFAIP3, CXCR4, CCL18).
Since the patient population included in this 
study was relatively small, we were unable to study 
specific correlations between gene expression, 
cytogenetics, and clinical presentation. However 
there did not appear to be an association of previous 
treatment to the molecular signature, and speciﬁ  -
cally there was no effect of erythropoietin treatment 
on EPOR gene expression. These ﬁ  ndings strengthen 
our interpretation that low EPOR levels might be 
related to the pathophysiology of MDS, and might 
explain the heterogeneity of response to treatment 
with erythropoietin among MDS patients.
In conclusion, this study provides new data on 
gene expression in the different phases of MDS. 
Although no single gene can likely explain the 
pathophysiology of the disease, some of the dif-
ferences delineated in this study may prove relevant 
in our efforts to identify prognostic markers and 
therapeutic targets.
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